Jazz Pharmaceuticals plc
JAZZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001232524
In the last 90 days, Jazz Pharmaceuticals plc insiders filed 0 open-market purchases and 10 sales; 652 institutions reported holding it in 13F filings for Q2 2026, worth $15.5B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $15.8B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $41.4M in total
- 10
- 13F holdersQ2 2026, +78 vs. previous quarter
- 652
- 13F valueReported value at the end of Q2 2026
- $15.5B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $4.27B
- +4.9% year over year
- Net income, FY2025
- -$356.1M
- −163.6% year over year
- Free cash flow, FY2025
- $1.30B
- −4.5% year over year
- Revenue, Q3 FY2026
- $1.24B
- +10.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $356.1M (8.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.80M
- Shares sold short
- Change
- −65.4K
- −1.1% vs. previous
- Days to cover
- 7.67
- At average daily volume
Superinvestors holding JAZZ, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding JAZZ at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Jazz Pharmaceuticals plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 (view filing)4:46 PM ET | Nov 6 | 4 days | Cozadd Bruce CDirector | SSale | −68.8K | $235.95 | −$16.2M | −16.1%357.6K after | 4 lots |
| Nov 6, 2026 (view filing)5:19 PM ET | Nov 4 | 2 days | Carr PatriciaSVP, Chief Accounting Officer | SSale | −1.41K | $231.36 | −$326.9K | −17.8%6.51K after | 2 lots |
| Nov 5, 2026 (view filing)6:28 PM ET | Nov 3 | 2 days | Gala Renee DPresident & CEO | SSale | −1.00K | $225.37 | −$225.4K | −0.7%140.4K after | 10b5-1 |
| Nov 4, 2026 (view filing)6:35 PM ET | Nov 2 | 2 days | Cozadd Bruce CDirector | SSale | −6.00K | $215.84 | −$1.30M | −1.7%339.9K after | 10b5-1 |
| Oct 7, 2026 (view filing)5:44 PM ET | Oct 6 | 1 day | Gala Renee DPresident & CEO | SSale | −2.00K | $236.40 | −$472.8K | −1.4%141.4K after | 10b5-1 |
| Oct 5, 2026 (view filing)4:18 PM ET | Oct 1 | 4 days | Cozadd Bruce CDirector | SSale | −6.00K | $230.33 | −$1.38M | −1.7%345.9K after | 10b5-1 |
| Sep 14, 2026 (view filing)6:38 PM ET | Sep 10 | 4 days | Patil Neena MEVP & Chief Legal Officer | SSale | −1.20K | $240.94 | −$289.1K | −2.5%47.7K after | 10b5-1 |
| Sep 10, 2026 (view filing)4:33 PM ET | Sep 8 | 2 days | Gala Renee DPresident & CEO | SSale | −2.00K | $243.03 | −$486.1K | −1.4%143.4K after | 10b5-1 |
| Sep 2, 2026 (view filing)5:03 PM ET | Sep 1 | 1 day | Cozadd Bruce CDirector | SSale | −6.00K | $250.13 | −$1.50M | −1.7%351.9K after | 10b5-1 |
| Aug 31, 2026 (view filing)6:45 PM ET | Aug 27 | 4 days | Iannone RobertEVP, Global Head of R&D & CMO | SSale | −76.9K | $249.70 | −$19.2M | −53.9%65.7K after | 6 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 652 holdersThe largest institutional positions in Jazz Pharmaceuticals plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,968,603 | $1.44B | 0.02% | +376,903+6.7% | Added |
| FMR LLC | 4,609,326 | $1.11B | 0.05% | +2,333,564+102.5% | Added |
| Vanguard Portfolio Management LLC | 3,036,213 | $731.6M | 0.03% | +52,971+1.8% | Added |
| Vanguard Capital Management LLC | 2,729,650 | $657.8M | 0.01% | +81,317+3.1% | Added |
| Capital World Investors | 2,697,610 | $650.0M | 0.08% | +24,234+0.9% | Added |
| LSV Asset Management | 2,275,145 | $548.2M | 0.99% | −111,695−4.7% | Reduced |
| Franklin Resources Inc | 2,040,250 | $491.6M | 0.11% | +81,310+4.2% | Added |
| State Street Corp | 1,999,816 | $481.9M | 0.01% | +108,170+5.7% | Added |
| Dimensional Fund Advisors LP | 1,713,592 | $412.9M | 0.07% | −181,623−9.6% | Reduced |
| Fuller & Thaler Asset Management, Inc. | 1,638,544 | $394.8M | 1.08% | −37,598−2.2% | Reduced |
Holders of 5% or more of JAZZ
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Jazz Pharmaceuticals plc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 8.60%5.60M shares | +1.20 ppfrom 7.40% | Feb 8, 20214 filings | Nov 5, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.04%3.10M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Politician trades
All politician trades in JAZZ2 members of Congress reported 4 trades in Jazz Pharmaceuticals plc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 13, 2023 |  Daniel S. Goldman House · NY | Sell | $15K-$50K |
| Apr 17, 2023 | Daniel S. Goldman House · NY | Buy | $15K-$50K |
| Feb 24, 2023 | Daniel S. Goldman House · NY | Sell | $1K-$15K |
| Nov 5, 2021 |  Thomas R. Suozzi House · NY | Buy | $1K-$15K |
House · NY · Aug 13, 2023
Sell$15K-$50K
House · NY · Apr 17, 2023
Buy$15K-$50K
House · NY · Feb 24, 2023
Sell$1K-$15K
House · NY · Nov 5, 2021
Buy$1K-$15K